Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Western Ontario

$22,000.00

Quantitative 3D digital pathology image analysis for tissue characterization on prostate cancer imaging

EF 2012-13

Résumé
Medical imaging technologies such as magnetic resonance imaging and computed tomography are important to our understanding of prostate cancer. Effective use these technologies requires knowledge of what the images tell us about disease severity. Men often undergo prostate removal surgery for cancer treatment; assessment of the removed tissue under a microscope gives reliable cancer severity information. Most of what we know about the relationship between medical image appearance and cancer disease status was learned by comparing pre-surgical medical images to the post-surgical microscopic assessment of disease status. However, there is a lack of proper tools to assist experts in quantitatively and repeatably making these assessments, and this has hindered our understanding of the most effective ways to use prostate medical imaging to help patients. This lack of tools makes it difficult for experts to consistently report on the precise locations, shapes, sizes, and appearances of cancerous tumours, so instead these attributes are reported in an inexact way or not at all. The main reason for the lack of necessary tools is that images of microscopic tissue samples are extremely large and until recently, computer hardware was not sufficient to store and process them. Experts have therefore been limited to making assessments by looking through microscopes at tissue mounted on glass slides - this makes tasks like outlining the detailed boundaries of tumours on the tissue impossible to perform accurately and quickly. Recently, this has changed, and digital pathology imaging systems now enable tissue assessments on the computer screen. This presents us with an opportunity to develop new software technologies to provide assistive tools that allow viewing of tissue samples not only in two dimensions, but also in three dimensions (3D), and allow the accurate determination of the 3D size, shape, appearance, and location of each tumour. The development of these software technologies is the theme of this proposal, which leverages the shift to the digital pathology paradigm to develop transformative technologies enabling a deeper understanding of the meaning and effective use of medical imaging for prostate cancer diagnosis and therapy guidance.
Programme
Discovery Grants Program - Individual
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
418740-2012
Name nom
Ward, Aaron
Department département
Medical Biophysics
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
22000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3113
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biophysics
Research subject fr
Biophysique
Partie
1
Nb partie
5
Application title
Quantitative 3D digital pathology image analysis for tissue characterization on prostate cancer imaging
Keyword
NSERC
Application summary
Medical imaging technologies such as magnetic resonance imaging and computed tomography are important to our understanding of prostate cancer. Effective use these technologies requires knowledge of what the images tell us about disease severity. Men often undergo prostate removal surgery for cancer treatment; assessment of the removed tissue under a microscope gives reliable cancer severity information. Most of what we know about the relationship between medical image appearance and cancer disease status was learned by comparing pre-surgical medical images to the post-surgical microscopic assessment of disease status. However, there is a lack of proper tools to assist experts in quantitatively and repeatably making these assessments, and this has hindered our understanding of the most effective ways to use prostate medical imaging to help patients. This lack of tools makes it difficult for experts to consistently report on the precise locations, shapes, sizes, and appearances of cancerous tumours, so instead these attributes are reported in an inexact way or not at all. The main reason for the lack of necessary tools is that images of microscopic tissue samples are extremely large and until recently, computer hardware was not sufficient to store and process them. Experts have therefore been limited to making assessments by looking through microscopes at tissue mounted on glass slides - this makes tasks like outlining the detailed boundaries of tumours on the tissue impossible to perform accurately and quickly. Recently, this has changed, and digital pathology imaging systems now enable tissue assessments on the computer screen. This presents us with an opportunity to develop new software technologies to provide assistive tools that allow viewing of tissue samples not only in two dimensions, but also in three dimensions (3D), and allow the accurate determination of the 3D size, shape, appearance, and location of each tumour. The development of these software technologies is the theme of this proposal, which leverages the shift to the digital pathology paradigm to develop transformative technologies enabling a deeper understanding of the meaning and effective use of medical imaging for prostate cancer diagnosis and therapy guidance.